Apr 4, 2025 8:30 am EDT RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
Apr 1, 2025 8:30 am EDT RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Mar 28, 2025 8:00 am EDT RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
Mar 26, 2025 8:00 am EDT RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
Mar 20, 2025 8:00 am EDT RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
Mar 19, 2025 8:00 am EDT RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
Feb 26, 2025 8:00 am EST RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
Feb 13, 2025 8:00 am EST RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
Feb 11, 2025 7:00 am EST RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
Feb 6, 2025 8:49 pm EST RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock